HIPK2 deficiency causes chromosomal instability by cytokinesis failure and increases tumorigenicity

Oncotarget

Volumn 6, Issue 12, 2015, Pages 10320-10334

  Valente, Davide ^a   Bossi, Gianluca ^a   Moncada, Alice ^a,g   Tornincasa, Mara ^b   Indelicato, Stefania ^c   Piscuoglio, Salvatore ^d,h   Karamitopoulou, Eva Diamantis ^e   Bartolazzi, Armando ^c   Pierantoni, Giovanna Maria ^b   Fusco, Alfredo ^b   Soddu, Silvia ^a   Rinaldo, Cinzia ^a,f  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e UNIVERSITY OF BERN   (Switzerland)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g CATHOLIC UNIVERSITY   (Italy)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

CIN; Cytokinesis failure; HIPK2; Near tetraploidy; Tumorigenicity

Indexed keywords

HOMEODOMAIN INTERACTING PROTEIN KINASE 2; PROTEIN P53; CARRIER PROTEIN; HIPK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ANEUPLOIDY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRADING; CARCINOGENICITY; CELL CYCLE ARREST; CELL IMMORTALIZATION; CELL PROLIFERATION; CHROMOSOMAL INSTABILITY; CONTROLLED STUDY; CYTOKINESIS FAILURE; E1A ONCOGENE; EMBRYO; FEMALE; FIBROBLAST; IN VIVO STUDY; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; NUCLEAR SIZE; ONCOGENE; ONCOGENE H RAS; PANCREAS ADENOCARCINOMA; PROTEIN EXPRESSION; TETRAPLOIDY; ANIMAL; CARCINOGENESIS; CELL DIFFERENTIATION; CYTOKINESIS; DEFICIENCY; GENETIC TRANSFECTION; GENETICS; HELA CELL LINE; HUMAN; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CARCINOGENESIS; CARRIER PROTEINS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHROMOSOMAL INSTABILITY; CYTOKINESIS; FEMALE; HELA CELLS; HUMANS; MICE; MICE, NUDE; PROTEIN-SERINE-THREONINE KINASES; TRANSFECTION;

EID: 84929598214     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3583     Document Type: Article

References (50)

1. D'Orazi G, Rinaldo C, Soddu S. Updates on HIPK2: a resourceful oncosuppressor for clearing cancer. J Exp Clin Cancer Res. 2012; 31: 63.
2. Schmitz ML, Rodriguez-Gil A, Hornung J. Integration of stress signals by homeodomain interacting protein kinases. Biol Chem. 2014; 95: 375-86.
3. Hofmann TG, Glas C, Bitomsky N. HIPK2: A tumour suppressor that controls DNA damage-induced cell fate and cytokinesis. Bioessays. 2013; 35: 55-64.
4. Wei G, Ku S, Ma GK, Saito S, Tang AA, Zhang J, Mao JH, Appella E, Balmain A, Huang EJ. HIPK2 represses beta-catenin-mediated transcription, epidermal stem cell expansion, and skin tumorigenesis. Proc Natl Acad Sci USA. 2007; 104: 13040-5.
5. Mao JH, Wu D, Kim IJ, Kang HC, Wei G, Climent J, Kumar A, Pelorosso FG, DelRosario R, Huang EJ, Balmain A. Hipk2 cooperates with p53 to suppress γ-ray radiationinduced mouse thymic lymphoma. Oncogene. 2012; 31:1176-80.
6. Krieghoff-Henning E, Hofmann TG. HIPK2 and cancer cell resistance to therapy. Future Oncol. 2008; 6: 751-4.
7. Puca R, Nardinocchi L, Givol D, D'Orazi G. Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells. Oncogene. 2010; 29: 4378-87.
8. Wiggins AK, Wei G, Doxakis E, Wong C, Tang AA, Zang K, Luo EJ, Neve RL, Reichardt LF, Huang EJ. Interaction of Brn3a and HIPK2 mediates transcriptional repression of sensory neuron survival. J Cell Biol. 2004; 167: 257-67.
9. Isono K, Nemoto K, Li Y, Takada Y, Suzuki R, Katsuki M, Nakagawara A, Koseki H. Overlapping roles for homeodomain-interacting protein kinases hipk1 and hipk2 in the mediation of cell growth in response to morphogenetic and genotoxic signals. Mol Cell Biol. 2006; 26: 2758-71.
10. Sung KS, Lee YA, Kim ET, Lee SR, Ahn JH, Choi CY. Role of the SUMO-interacting motif in HIPK2 targeting to the PML nuclear bodies and regulation of p53. Exp Cell Res. 2011; 317:1060-70.
11. Iacovelli S, Ciuffini L, Lazzari C, Bracaglia G, Rinaldo C, Prodosmo A, Bartolazzi A, Sacchi A, Soddu S. HIPK2 is involved in cell proliferation and its suppression promotes growth arrest independently of DNA damage. Cell Prolif. 2009; 42: 373-84.
12. Hattangadi SM, Burke KA, Lodish HF. Homeodomaininteracting protein kinase 2 plays an important role in normal terminal erythroid differentiation. Blood. 2010; 115:4853-61.
13. Rinaldo C, Moncada A, Gradi A, Ciuffini L, D'Eliseo D, Siepi F, Prodosmo A, Giorgi A, Pierantoni GM, Trapasso F, Guarguaglini G, Bartolazzi A, Cundari E, et al. HIPK2 controls cytokinesis and prevents tetraploidization by phosphorylating histone H2B at the midbody. Mol Cell. 2012; 47: 87-98.
14. Castedo M, Senovilla L, Vitale I, Kroemer G. Tetraploid cancer cell precursors in ovarian carcinoma. Cell Cycle. 2012; 11:3157-8.
15. Margolis RL. Tetraploidy and tumor development. Cancer Cell 2005; 8:353-4.
16. Fujiwara T, Bandi M, Nitta M, Ivanova EV, Bronson RT, Pellman D. Cytokinesis failure gene rating tetraploids promotes tumorigenesis in p53-null cells. Nature. 2005; 437: 1043-7.
17. Ganem NJ, Godinho SA, Pellman D. A mechanism linking extra centrosomes to chromosomal instability. Nature. 2009; 460: 278-82.
18. Vitale I, Galluzzi L, Senovilla L, Criollo A, Jemaà M, Castedo M, Kroemer G. Illicit survival of cancer cells during polyploidization and depolyploidization. Cell Death Differ. 2011; 8: 1403-13
19. Thompson SL, Compton DA. Examining the link between chromosomal instability and aneuploidy in human cells. J Cell Biol. 2008; 180: 665-72.
20. Thompson SL, Compton DA. Proliferation of aneuploid human cells is limited by a p53-dependent mechanism. J Cell Biol. 2010; 188: 369-81.
21. Ganem NJ, Cornils H, Chiu SY, O'Rourke KP, Arnaud J, Yimlamai D, Théry M, Camargo FD, Pellman D. Cytokinesis failure triggers hippo tumor suppressor pathway activation. Cell. 2014; 158:833-48.
22. Ganem NJ, Pellman D. Limiting the proliferation of polyploidy cells. Cell. 2007; 131: 437-40.
23. Kwon M, Godinho SA, Chandhok NS, Ganem NJ, Azioune A, Thery M, Pellman D. Mechanisms to suppress multipolar divisions in cancer cells with extra centrosomes. Genes Dev. 2008; 22: 2189-203.
24. Davoli T, de Lange T. The causes and consequences of polyploidy in normal development and cancer. Annu Rev Cell Dev Biol. 2011; 27: 585-610.
25. Weaver BA, Cleveland DW. Aneuploidy: instigator and inhibitor of tumorigenesis. Cancer Res. 2007; 67: 10103-5.
26. Ricke RM, van Deursen JM. Aneuploidy in health, disease, and aging. J Cell Biol. 2013; 201:11-21.
27. Galipeau PC, Cowan DS, Sanchez CA, Barrett MT, Emond MJ, Levine DS, Rabinovitch PS, Reid BJ. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc Natl Acad Sci USA. 1996; 93: 7081-4.
28. Olaharski AJ, Sotelo R, Solorza-Luna G, Gonsebatt ME, Guzman P, Mohar A, Eastmond DA. Tetraploidy and chromosomal instability are early events during cervical carcinogenesis. Carcinogenesis. 2006; 27: 337-43.
29. Sato N, Mizumoto K, Nakamura M, Nakamura K, Kusumoto M, Niiyama H, Ogawa T, Tanaka M. Centrosome abnormalities in pancreatic ductal carcinoma. Clin Cancer Res. 1999; 5: 963-70.
30. Tanaka T, Mori H, Takahashi M, Williams GM. DNA content of hyperplastic and neoplastic acinar cell lesions in rat and human pancreas. J Exp Pathol. 1984; 1:315-26
31. Hruban RH, Takaori K, Canto M, Fishman EK, Campbell K, Brune K, Kern SE, Goggins M. Clinical importance of precursor lesions in the pancreas. J Hepatobiliary Pancreat Surg. 2007; 14: 255-63.
32. Maitra A, Hruban RH. Pancreatic cancer. Annu Rev Pathol 2008; 3: 157-88.
33. Woo RA, Poon RY. Activated oncogenes promote and cooperate with chromosomal instability for neoplastic transformation. Genes Dev. 2004; 18: 1317-30.
34. Nicholson JM, Cimini D. Doubling the deck: Tetraploidy induces chromosome shuffling and cancer. Cell Cycle. 2012; 11: 3354-5.
35. Senovilla L, Vitale I, Martins I, Tailler M, Pailleret C, Michaud M, Galluzzi L, Adjemian S, Kepp O, Niso-Santano M, Shen S, Mariño G, Criollo A, et al. An immunosurveillance mechanism controls cancer cell ploidy. Science. 2012; 337: 1678-84.
36. Rinaldo C, Prodosmo A, Siepi F, Soddu S. HIPK2: a multitalented partner for transcription factors in DNA damage response and development. Biochem Cell Biol. 2007; 85: 411-8.
37. Lazzari C, Prodosmo A, Siepi F, Rinaldo C, Galli F, Gentileschi M, Bartolazzi A, Costanzo A, Sacchi A, Guerrini L, Soddu S. HIPK2 phosphorylates ΔNp63α and promotes its degradation in response to DNA damage. Oncogene. 2011; 30: 4802-13.
38. Piscuoglio S, Zlobec I, Pallante P, Sepe R, Esposito F, Zimmermann A, Diamantis I, Terracciano L, Fusco A, Karamitopoulou E. HMGA1 and HMGA2 protein expression correlates with advanced tumour grade and lymph node metastasis in pancreatic adenocarcinoma. Histopathology. 2012; 60: 397-404.
39. de la Vega L, Grishina I, Moreno R, Krüger M, Braun T, Schmitz ML. A redox-regulated SUMO/acetylation switch of HIPK2 controls the survival threshold to oxidative stress. Mol Cell. 2012; 46: 472-83.
40. Lavra L, Rinaldo C, Ulivieri A, Luciani E, Fidanza P, Giacomelli L, Bellotti C, Ricci A, Trovato M, Soddu S, Bartolazzi A, Sciacchitano S. The loss of the p53 activator HIPK2 is responsible for galectin-3 overexpression in well differentiated thyroid carcinomas. PLoS One. 2011; 6:e20665.
41. Li XL, Arai Y, Harada H, Shima Y, Yoshida H, Rokudai S, Aikawa Y, Kimura A, Kitabayashi I. Mutations of the HIPK2 gene in acute myeloid leukemia and myelodysplastic syndrome impair AML1- and p53-mediated transcription. Oncogene. 2007; 26: 7231-9.
42. Deshmukh H, Yeh TH, Yu J, Sharma MK, Perry A, Leonard JR, Watson MA, Gutmann DH, Nagarajan R. High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas. Oncogene. 2008; 27: 4745-51.
43. van Heek T, Rader AE, Offerhaus GJ, McCarthy DM, Goggins M, Hruban RH, Wilentz RE. K-ras, p53, and DPC4(MAD4) alterations in fine-needle aspirates of the pancreas:a molecular panel correlates with and supplements cytologic diagnosis. Am J Clin Pathol. 2002; 117: 755-65.
44. Sphyris N, Harrison DJ. p53 deficiency exacerbates pleiotropic mitotic defects, changes in nuclearity and polyploidy in transdifferentiating pancreatic acinar cells. Oncogene. 2005; 24: 2184-94.
45. Hruban RH, Iacobuzio-Donahue C, Wilentz RE, Goggins M, Kern SE. Molecular pathology of pancreatic cancer. Cancer J. 2001; 7: 251-8.
46. Hruban RH, Maitra A, Kern SE, Goggins M. Precursors to pancreatic cancer. Gastroenterol Clin North Am. 2007; 36:831-49.
47. Hruban RH, Fukushima N. Pancreatic adenocarcinoma:update on the surgical pathology of carcinomas of ductal origin and PanINs. Mod Pathol. 2007; 20: S61-70.
48. Cicalese A, Bonizzi G, Pasi CE, Faretta M, Ronzoni S, Giulini B, Brisken C, Minucci S, Di Fiore PP, Pelicci PG. The tumor suppressor p53 regulates polarity of selfrenewing divisions in mammary stem cells. Cell. 2009; 138:1083-95.
49. Gurtner A, Fuschi P, Martelli F, Manni I, Artuso S, Simonte G, Ambrosino V, Antonini A, Folgiero V, Falcioni R, Sacchi A, Piaggio G. Transcription factor NF-Y induces apoptosis in cells expressing wild-type p53 through E2F1 upregulation and p53 activation. Cancer Res. 2010; 70:9711-20.
50. Land H, Parada LF, Weinberg RA. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature. 1983; 304: 596-602.